|Mr. John L. Erb||Chairman, Chief Exec. Officer and Pres||613.75k||N/A||68|
|Ms. Claudia Napal Drayton||Chief Financial Officer and Sec.||327.21k||N/A||49|
|Mr. David Lerner||Sr. VP of R&D and Operations||N/A||N/A||N/A|
|Mr. Gordon S. Weber J.D.||VP and Gen. Counsel||N/A||N/A||N/A|
|Ms. Sandra Eayrs||VP of HR||N/A||N/A||N/A|
Sunshine Heart, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Sunshine Heart, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Sunshine Heart, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.